Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary …
Author
Tonix Pharmaceuticals Holding Corp.
-
-
Bone marrow transplantion
Tonix Pharmaceuticals completes Phase 1 clinical trial of TNX-1500 (Fc-modified humanized anti-CD40L monoclonal antibody) in healthy volunteers
Tonix Pharmaceuticals Holding Co., Ltd. Top-line results are expected in the third quarter of 2024.Planning phase 2 trial to prevent kidney transplant rejection Anti-CD40L has multiple potential indications in addition …